A new study led by the University of Oxford has revealed that a common and usually harmless virus may positively influence how skin cancer patients respond to current treatments.
University of Oxford researcher, Katherine Vallis, has been awarded new funding from the MRC to launch a project on the use of cell-permeant antibodies for the treatment of acute leukaemia. The funding will allow Prof. Vallis and her team to generate in vivo data on the use of cell-penetrating peptides (CPPs) for cancer applications, a crucial step towards clinical translation.
A team of researchers at the Department of Oncology have uncovered a key mechanism by which cells respond to their physical environment. In a pioneering study, published in Science Advances, Eric O\u2019Neill and his team describe a new signalling cascade, through which mechanical forces trigger the assembly of nuclear actin, crucial for nuclear integrity. Moreover, a common mutation in this pathway, present in ~10% of the population, was shown to associate with schizophrenia, anxiety, and depression, underscoring the importance of mechanical signalling in the nucleus for brain health.
We are proud to share the success of two early-career postdoctoral researchers at the Department of Oncology, Ahmet Hazini and Esther Ng, who have secured funding to deliver pioneering research projects that aim to advance the field of cancer immunotherapy.
Global biopharma company GSK invests up to \u00a350 million in a collaboration with Oxford to advance the understanding of how cancer develops, which could inform future development of vaccines to prevent cancer.
Researchers from the University of Oxford have developed TriOx, a highly sensitive blood test that detects six cancers at their earliest stages. Published today in Nature Communications, the findings highlight the test\u2019s potential to transform early cancer detection and improve patient outcomes.
The Department of Oncology at the University of Oxford is delighted to announce that our new MSc Medical Physics with Radiobiology programme has received Masters Level Accreditation from the Institute of Physics and Engineering Medicine (IPEM).
The Oncology Department at the University of Oxford is excited to announce the forthcoming publication in the Proceedings of the National Academy of Sciences (PNAS) of the research paper \u201cGoblet Cell Differentiation Subgroups in Colorectal Cancer.\u201d This groundbreaking study sheds light on the role of goblet cell differentiation in colorectal cancer (CRC) and its impact on cancer progression and prognosis.
A team of international researchers at the University of Oxford (Oxford) and Nanyang Technological University, Singapore (NTU Singapore), has discovered a new process for repairing damaged DNA that is particularly relevant for patients undergoing colorectal cancer treatments.
A pioneering study, led by UK universities, including the University of Oxford, The Institute of Cancer Research, London, the University of Manchester and the University of Leeds, has provided the most comprehensive analysis to date of the genetic makeup of colorectal cancer (CRC).
Subashan Vadibeler, a recent Oxford Rhodes scholar and Department of Oncology student, is one of five co-winners of the international 2024 Lasker Essay Contest, sponsored by the Lasker Foundation.
A glowing marker dye that sticks to prostate cancer cells could help surgeons to remove them in real-time, according to a study led by the University of Oxford.
Oxford and UCL researchers seeking to create the world\u2019s first vaccine to prevent lung cancer in people at high risk of the disease have been granted up to \u00a31.7 million from Cancer Research UK and the CRIS Cancer Foundation.
The technique, which builds on recent advances in decentralised machine learning, uses inexpensive pre-programmed micro-computers, making it easy to deploy in hospitals and cheap to scale up.
Winners of the Medical Research Foundation's second Festive Science Image Competition, run in partnership with the Medical Research Council (MRC), have been announced today.
Dr Robert Watson has won one of three McElwain and President's Prizes from the Association of Cancer Physicians for his DPhil work undertaken with Professor Ben Fairfax.
SerenOx Africa aims to address diagnostic gaps for common blood disorders through a testing facility for key underserved patient populations in Tanzania. This facility will also aim to provide early cancer detection for high-risk patients.
Eileen Parkes, Associate Professor in Innate Tumour Immunology in the Department of Oncology, will lead the expansion of the centre\u2019s programmes in early drug development and biomarker research.
![\"\"](\"https://www.oncology.ox.ac.uk/news/new-study-finds-common-virus-may-improve-skin-cancer-treatment-outcomes/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n